sMRI-Guided Dose-Escalated RT for Glioblastoma

Phase 2, open-label, single-arm trial in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Emory University. Primary endpoints: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform up to 2 years and Incidence of Adverse Event Assessed by Common Terminology Criteria for Adverse Events Version 4.0 up to 2 years. Started Sep 2017; status: completed.